Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. The market for medical cannabis in Germany.

Access 105

Access Research and Development Pharmaceutical Therapy 105

Cannabis Law Report

SEPTEMBER 2, 2022

The pharmaceutical industry takes a serious economic hit after states legalize marijuana—with an average market loss of nearly $10 billion for drugmakers per each legalization event—according to a first-of-its-kind study. By expanding access and, thus use, legalization could permit cannabis to compete with conventional pharmaceuticals. “By

Pharmaceutical 52

Pharmaceutical Legalization Marijuana Data 52

Veriheal

SEPTEMBER 16, 2020

Epidiolex is the sole cannabis-derived pharmaceutical that has been approved by the FDA – although it is worth noting that the organization has also approved three synthetic cannabis-related products. The FDA Adds a New Condition for Treatment. However, there is one notable example—Epidiolex. What is Epidiolex?

Access 98

Access Epilepsy Treatment Conditions 98

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

In either case, there is definitely a connection, and the widening availability for adults to consume cannabis legally for recreational and medicinal purposes has driven public interest into using cannabis for mental health treatment. Between CBD and THC, CBD seems to hold the best potential as a treatment for anxiety compared to THC.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Canna Care Docs

NOVEMBER 4, 2024

cannabis has been used medicinally as a treatment for pain and other ailments. Today, you can explore personalized treatment plans to aid your distinctive needs. Patients with these conditions frequently seek relief from a variety of traditional treatments. Medicine and orthopedic concept. Since 2727 B.C.

Chronic Pain 111

Chronic Pain Nerve Pain Treatment Cannabinoids 111

Cannabis Law Report

JUNE 23, 2021

Valcon Medical A/S Announces Receipt of EU GMP Certification and Start of Commercial Production for Pharmaceutical-Grade Cannabis Concentrates, Intermediary Products, and Medical Formulations (PRNewsfoto/Valcon Medical A/S).

Pharmaceutical 86

Pharmaceutical Concentrates Extraction Medicine 86

CannaTech

JANUARY 16, 2019

Pharmaceutical grade cannabis is relatively new in parts of the world. Patients, and their treatment, therefore, are the priority. Treatment options may be limited by government-approved imports, a practitioner’s prescription or pharmacy stock. Legal access does not necessarily equate to financial access.

Access 89

Access Patients Pharmaceutical Education 89

Cannabis Info

MARCH 2, 2019

Marijuana as a treatment for epilepsy. Medical cannabis is showing great potential in the treatment of epilepsy. CONVENTIONAL TREATMENT. One of the goals of treating epilepsy is to allow people to continue to live functional and fulfilling life’s epilepsy treatment. CANNABIS AS A POTENTIAL TREATMENT.

Epilepsy 69

Epilepsy Treatment Marijuana Research and Development 69

Cannabis Law Report

JANUARY 6, 2022

An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. Mental health treatment is big business, with the global antidepressant drug market valued at over $13 billion in 2016. Threat to Patient Access in Oregon. The Race to Patent Psilocybin.

Access 52

Access Patients Research and Development Treatment 52

Cannabis Law Report

AUGUST 17, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. Chief Medical Officer of Marinus. “We Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Veriheal

JULY 26, 2023

Georgia medical cannabis patients will soon have greater access to treatment as cannabis oil will be sold in many more pharmacies. Eligible patients were granted access to low-THC marijuana oil. Andrew Turnage, the executive director of the Georgia Access to Medical Cannabis Commission, spoke on this fact.

Oil 98

Oil Patients Access THC 98

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Support for Patient Well-Being The availability of medical marijuana in local communities fosters an environment of support for patients seeking alternative treatments.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

The Fresh Toast

DECEMBER 21, 2021

As cannabis becomes less stigmatized, the autism community is exploring treatments that are more accessible and less pharmaceutical. THC More Effective Than CBD In Treating Autism, New Preliminary Study Shows.

THC 105

THC CBD Pharmaceutical Treatment 105

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. Some parents, who have travelled to the Netherlands to buy cannabis medicines, feel the treatment will not help many children because it does not contain THC, which they argue has helped their children. ” Source BBC: [link].

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Veriheal

SEPTEMBER 23, 2021

Note: Veriheal does not support illegally consuming therapeutic substances such as Iboga but acknowledges that it transpires because of the current illicit status, which we strive to change by advocating for research, legal access, and responsible consumption. Always consult a physician before attempting alternative therapies.

Treatment 98

Treatment Medicine Research and Development Therapy 98

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

SEPTEMBER 22, 2022

The Federal Parliament legalised the use of medicinal cannabis products in Australia in February 2016, but access to treatment is still severely limited due to cost, with patients reporting average monthly costs in excess of $300 , or approximately $10 per day. He writes on his website. List Medicinal Cannabis on the PBS.

Pharmaceutical 52

Pharmaceutical Media Medicine Treatment 52

LifeCannMD

AUGUST 30, 2024

Among them, one Medical Marijuana doctor stands out, offering compassionate care and expert guidance to patients seeking alternative treatments. Coconut Grove has embraced this change, with residents increasingly turning to medical cannabis as a natural alternative to traditional pharmaceuticals.

Marijuana 52

Marijuana Chronic Pain Treatment Pharmaceutical 52

Veriheal

SEPTEMBER 27, 2021

The United Kingdom’s Multiple Sclerosis (MS) Society has taken a stand against restricted access to medical cannabis in the country. Medical cannabis has been legal in the nation for almost three years—so why are MS patients struggling to access the treatment? Yet many people with MS are still unable to access it.”

Treatment 98

Treatment Patients Access Research and Development 98

NORML

MAY 26, 2020

Thus, it enables individualization of medical cannabis regimens that can be evaluated pharmacokinetically and pharmacodynamically by accepted pharmaceutical models.” Chronic pain is the most commonly reported qualifying condition among medical cannabis patients enrolled in state-specific access programs.

Clinical Trials 245

Clinical Trials Chronic Pain Cannabinoids Patients 245

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

MAY 2, 2023

Australian cannabis company Cannatrek has launched a not-for-profit organisation dedicated to providing support and access to medicinal cannabis therapies for vulnerable groups. Medicinal cannabis is still quite expensive, […]

Therapy 52

Therapy Pharmaceutical Medicine Treatment 52

The Fresh Toast

AUGUST 19, 2019

With the stigma of cannabis fading by the day, more families are exploring treatments that are more accessible and less pharmaceutical. Continue reading The Potential Of CBD And Cannabis Within The Anxiety And Autism Community at The Fresh Toast.

CBD 111

CBD Pharmaceutical Treatment Access 111

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

MGC Pharma

FEBRUARY 22, 2018

While at home in Australia, the Medical Cannabis industry is still working hard to gather more evidence-based research to substantiate treatment assertions, relevant studies are already occurring overseas. It’s heartening to see the release of more and more evidence-based global research surrounding Medical Cannabis-based treatment.

Research and Development 100

Research and Development Pharmaceutical Chronic Pain Treatment 100

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Accessed July 25, 2021. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Google Translation.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

NORML

JULY 1, 2019

Three new laws intended to expand patient access to and the therapeutic value of Virginia’s medical cannabis program take effect July 1, 2019. “This year, my focus was on program improvements to further expand both access and therapeutic value to benefit the health and well-being of all Virginians.”

Law 253

Law Patients Access Oil 253

MMJ Recs

MAY 23, 2024

Treatments for chronic conditions are hard as many individuals grapple with ongoing health issues and often find themselves in a perpetual search of what works to manage symptoms and find relief. However, for many individuals, these conventional treatments may fall short of providing adequate relief or come with undesirable side effects.

Conditions 105

Conditions Chronic Pain Therapy Marijuana 105

Cannabis Law Report

AUGUST 9, 2021

We will be able to benefit broader medical needs, by making treatment options accessible, through innovative products that are tailored to medical needs that do not exist today,” says Dr. Hadile Ounallah-Saad, VP of R&D. The patent approval is significant for the medical cannabis market. Of Cannassure.

Cannabinoids 98

Cannabinoids Pharmaceutical Treatment Patients 98

Cannabis Law Report

JULY 21, 2022

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Kabir Nath as Chief Executive Officer, effective August 1, 2022. London, UK July 19, 2022.

Therapy 52

Therapy Research and Development Pharmaceutical Patients 52

MMJ Recs

APRIL 1, 2024

We’re exploring the world of CBD, uncovering the benefits of CBD in medical marijuana, its impact on health, its potential as a treatment option, and what you need to know about its use in medical marijuana. CBD: A Promising Treatment Option One of the most compelling aspects of CBD is its versatility as a treatment option.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

MMJ Recs

FEBRUARY 3, 2024

Pennsylvania Medical Cannabis Program and Philadelphia Marijuana Dispensaries The Pennsylvania Medical Cannabis Program serves as the foundation for medical marijuana accessibility in Philadelphia. In Philadelphia, patients must be diagnosed with specific medical conditions to be eligible for medical cannabis treatment.

Legislation 52

Legislation Law Marijuana Dispensary 52

MMJ Recs

MARCH 23, 2024

Legalization may offer expanded access to medical cannabis for patients suffering from various conditions, providing alternative treatment options and symptom relief. However, challenges remain in ensuring equitable access to participation in the legal cannabis market and addressing disparities in ownership and representation.

Legalization 52

Legalization Access Programs Education 52